CAR T Cell Therapy in Cancer: Progress and Challenges Across Solid and Hematologic Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 7
Special Issue Editors
Interests: integrins; cancer microenvironment; tumour invasion; tumour biology; protein structure; biomarker; therapeutic targeting
Special Issues, Collections and Topics in MDPI journals
Interests: CAR-T therapy; integrins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated remarkable clinical success in the treatment of several hematologic malignancies, leading to durable remissions in patients with otherwise refractory disease. Despite these successes, translating this approach to solid tumors has proven significantly more complex.
Barriers such as poor T cell infiltration, antigen heterogeneity, and the immunosuppressive tumor microenvironment continue to hinder efficacy in solid tumors. Meanwhile, resistance and relapse remain concerns even in hematologic settings, underscoring the need for continued innovation and mechanistic insight across cancer types.
This Special Issue aims to explore the evolving field of CAR T-cell therapy across both solid and blood cancers. We invite contributions that address key challenges, novel engineering approaches, strategies to overcome resistance mechanisms, and emerging clinical applications.
By bringing together experts from across the CAR T cell therapy landscape, we aim to highlight the progress made and the ongoing challenges that must be addressed to expand the therapeutic impact of CAR T cells across the full spectrum of malignancies.
Prof. Dr. John F. Marshall
Dr. Lauren C. Cutmore
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR-T cell therapy
- adoptive cell therapy
- immunotherapy
- antigen escape
- solid tumor
- hematologic malignancies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
